Searched for
INTAS PHARMA COMPANY
Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Cancer drug makers seek 50% price hike as platinum surge hits production viabilityLocal drug manufacturers are struggling to produce essential cancer medicines like carboplatin and cisplatin due to a significant surge in ...
- Bankruptcy court admits BSE-listed Supha Pharmachem under Insolvency Resolution ProcessThe Mumbai bench of the National Company Law Tribunal has admitted Supha Pharmachem into the Corporate Insolvency Resolution Process (CIRP)...
- Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...
- Biosimilar brand buy to help Intas Pharma take on biggiesIn one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication peg...
- Indian pharma majors weigh bids for Sanofi’s $2 billion European generics businessThe portfolio of acute, chronic and oncology products could fetch a valuation of $1.5-2 bn, making it among the largest outbound transactio...
- ChrysCapital sells 3% in Intas to Capital InternationalChrysCapital will continue to hold a 3% stake in Intas, making it the longest and probably the most successful private equity investment in...
- Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players clubWith the acquisition of Teva’s products, sold through erstwhile Actavis’ operations, Intas is set to emerge as a top player in the UK gener...
- Intas Pharmaceuticals to launch its first biosimilar in US in 9-12 monthsIntas is the only domestic firm with two biosimilars filed for registration in the US and it looks to deliver affordable and innovative pha...
- 15 doctors suspended for accepting junketsThe doctors’ regulatory body is also in the process of sending a letter to the Drug Controller General of India, urging it to warn and take...
- Temasek completes 10.16% stake purchase in Intas PharmaTemasek acquired the stake by way of secondary purchase of shares from private equity investor ChrysCapital. This investment will deepen Te...
- Delhi High Court comes to Intas rescue, stops Arinna Lifescience for trademark violationDelhi High Court gave relief to Ahmedabad-based drug maker, Intas Pharmaceuticals, by granting an ex-parte injunction against the sale of V...
- ChrysCapital to sell 10% in drug maker Intas Pharmaceuticals to Temasek for over $160 millionTemasek has bought 12.5% stake in Intas Pharmaceuticals, one of India's top 10 drug makers by sale, for a little over Rs 1,100 crore, peopl...
- Temasek, two other PEs eye ChrysCapital’s 10 pc stake in Intas PharmaThree private equity funds are in independent talks to purchase rival ChrysCap’s stake Intas Pharmaceuticals for about $150 million or Rs 9...
- Intas ex-employee objects to amalgamation planAn affidavit of objection challenging Intas' amalgamation was filed by Mani Iyer, a former executive director of Intas Biopharmaceuticals, ...
- Intas gets SEBI nod for IPO for raising Rs 800 croreIntas Pharmaceuticals has received SEBI clearance for its IPO. The issue was expected to hit the market in May, but Intas is still undecide...
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
- Intas Pharma IPO to raise Rs 800 cr, fund acquisitionsIntas Pharma plans to raise Rs 750-800 cr through IPO that will help it raise fresh funds for acquisitions besides allowing PE investor Chr...
- Mauritius-based FIIs to pick up 47% in Intas' biotech armA clutch of investors are set to pick up 47% stake in the Intas Biopharmaceuticals, the biotech arm of Ahmedabad-based pharma major Intas P...
Load More
